At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
BI10773 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics and Pharmacodynamics of BI 10773 After Single and Multiple Oral Dose of 10 mg and 25 mg BI 10773 in Chinese Male and Female Type 2 Diabetic Patients
In Brief
A Phase 1 clinical trial evaluating BI10773 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 24 participants across 1 site.
Detailed Summary
the pharmacokinetics, pharmacodynamics and safety and tolerability of single and multiple oral doses of BI 10773 at low dose once daily (q.d.) and high dose q.d. administered to Chinese female and male patients with type 2 diabetes will be investigated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionJan 2012
TodayJul 2026
First PostedMar 16, 2011
Enrollment StartMar 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.3 years ago
Interventions
BI10773drug
patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
Placebodrug
patient to receive two placebos
Placebodrug
patient to receive two placebos
Placebodrug
patient to receive two placebos
BI10773drug
patient to receive a tablet containing low dose BI10773 p.o. plus one placebo